Table 2.
Change in secondary markers of lung function over 12 months of losartan therapy
N (%) | FEV1 | DLCO | 6MWT distance |
---|---|---|---|
Stable | 8 (47.06) | 10 (58.82) | 6 (35.29) |
Improved | 2 (11.76) | 2 (11.76) | 5 (29.41) |
Deteriorated | 7 (41.18) | 5 (29.42) | 6 (−1.38) |
FEV1 forced expiratory volume 1 second, DLCO diffusing capacity for carbon monoxide